EUCTR2012-004766-17-ES进行中（未招募）1 期
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 372
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Voluntarily signed and dated Institutional Review Board / Ethics Committee approved informed consent form in accordance with regulatory and institutional guidelines. Written informed consent must be obtained prior to performing any study-related procedure;
- •2) Males and female subjects ? 18 years of age at the time of enrollment;
- •3) Histologically confirmed diagnosis of MF or SS within 3 months of the Pre-treatment Visit;
- •a. For SS (defined as meeting T4 plus B2 criteria), where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either a node biopsy or fulfillment of B2 criteria including a clone in the blood that matches that of the skin.
- •4) Stage IB, II-A, II-B, III and IV;
- •5) Subjects who have progressed following at least one prior course of systemic therapy (e.g., interferon, denileukin diftitox, bexarotene, photopheresis, anti-neoplastic chemotherapy, etc.);
- •6) Eastern Cooperative Oncology Group (ECOG) performance status score of ? 1 at study entry;
- •7) The subject has resolution of all clinically significant toxic effects of prior cancer therapy to Grade ? 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI-CTCAE, v.4.0) excluding the specifications required in 8, 9 and 10 below.
- •8) Adequate hematological function:
- •a. absolute neutrophil count (ANC) ? 1,500 cells/?L (? 1,500/mm3)
- •b. platelets ? 100,000 cells/?L; (? 100,000/mm3)
- •c. in subjects with known bone marrow involvement, ANC must be ? 1,000 cells/?L (? 1,000/mm3) and platelets ? 75,000 cells/?L. (? 75,000/mm3)
- •9) Adequate hepatic function:
- •a. bilirubin ? 1.5 times the specific institutional upper limit of normal (ULN), except for subjects with Gilbert?s syndrome;
- •b. aspartate transaminase (AST) and alanine transaminase (ALT) each ? 2.5 x ULN or ? 5.0 x ULN in the presence of known hepatic malignancy.
- •10) Adequate renal function:
- •a. serum creatinine ? 1.5 x ULN;
- •b. calculated creatinine clearance > 50 mL/min using the Cockcroft-Gault formula.
- •11) Subjects previously treated with anti-CD4 antibody or alemtuzumab are eligible provided their CD4+ cell counts are ? 200/mm3.
- •12) Subjects with MF and a known history of non-complicated staphylococcus infection/colonization are eligible provided they continue to receive stable doses of prophylactic antibiotics.
- •13) Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication.
- •14) WOCBP must agree to use effective contraception, defined as oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice true abstinence from sexual intercourse (periodic abstinence, e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception) during the study and for 3 months after the last dose. WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea
- •? 12 consecutive months);
- •15) Male subjects and their female partners of child bearing potential must be willing to use an appropriate method of contraception defined as oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice true abstinence from sexual intercourse (periodic abstinence, e.g., calendar, ovulation, symptothermal, post-ovulation method
排除标准
- •1) Large cell transformation of SS as well as transformed MF;
- •2) Have had a malignancy in the past two years. However, subjects with non-melanoma skin cancers, melanoma in situ, localized cancer of the prostate with current prostate-specific antigen of < 0.1 ?g/mL (< 1 ng/mL), treated thyroid cancer or cervical carcinoma in situ or ductal/lobular carcinoma in situ of the breast with in the past two years may enroll as long as there is no current evidence of disease.
- •3) Clinical evidence of central nervous system (CNS) metastasis.
- •4) Psychiatric illness, disability or social situation that would compromise the subject?s safety or ability to provide consent, or limit compliance with study requirements.
- •5) Significant uncontrolled intercurrent illness including, but not limited to:
- •a. uncontrolled infection requiring antibiotics;
- •b. clinically significant cardiac disease (class III or IV of the New York Heart Association classification);
- •c. unstable angina pectoris;
- •d. angioplasty, stenting, or myocardial infarction within 6 months;
- •e. uncontrolled hypertension (systolic blood pressure (BP) > 160 mm Hg or diastolic BP
- •> 100 mm Hg, found on two consecutive measurements separated by a 1-week period) despite two anti-hypertensive medications;
- •f. clinically significant cardiac arrhythmia; or
- •g. uncontrolled diabetes.
- •6) Known or tests positive for human immunodeficiency virus, human T-cell leukemia virus, hepatitis B or hepatitis C.
- •7) Active herpes simplex or herpes zoster. Subjects on prophylaxis for herpes who started taking medication at least 30 days prior to study entry, and have no active signs of active infection, and whose last active infection was more than 6 months ago, may enter the study, and should continue to take the prescribed medication for the duration of the study.
- •8) Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins.
- •9) Known active autoimmune disease will be excluded. (For example; Graves? disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn?s disease; psoriasis).
- •10) Is pregnant (confirmed by beta human chorionic gonadotrophin [?-HCG]) or lactating.
- •11) Prior treatment with KW-0761.
- •12) Prior treatment with vorinostat.
- •13) Have had any therapy directed against the subject?s underlying cancer or any investigational medications within four weeks of randomization (skin directed treatments, including topicals and radiation within two weeks of randomization). However, subjects with rapidly progressive malignant disease may be enrolled prior to this period after discussion with the Medical Monitor.
- •14) Subjects on a stable dose of a low dose systemic corticosteroid (? 20 mg prednisone equivalent) for at least 4 weeks prior to study entry may continue use although the investigator should attempt to taper the use to the lowest dosage tolerable while on study. Initiation of treatment with systemic corticosteroids or increase in dose while on study is not permitted except to treat an infusion reaction. Subjects may receive intra-articular corticosteroid injections, intraocular corticosteriod drops, inhalation or nasal corticosteroids and replacement doses of systemic corticosteroids as needed.
- •15) Subjects on a stable dose of medium or low potency topical corticosteroids for at least 4 weeks prior to study entry may continue use at the same dose, although the investigator should attempt to taper the use to the lowest dosage tolerable while on study. Initiation of treatment with t
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to test if KW-0761 (an antibody) or a chemotherapy drug, called vorinostat, will work in patients with recurrent or unsuccessfully treated Cutaneous T-Cell Lymphoma.Treatment of subjects with previously treated cutaneous T-cell lymphomaMedDRA version: 22.0Level: PTClassification code 10011679Term: Cutaneous T-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004766-17-DKKyowa Kirin Pharmaceutical Development, Inc.317
已完成
3 期
Study of KW-0761 Versus Vorinostat In Relapsed/Refractory CTCL.JPRN-jRCT2080222561Kyowa Kirin Pharmaceutical Development, Inc.372
进行中（未招募）
1 期
A clinical trial to test if KW-0761 (an antibody) or a chemotherapy drug, called vorinostat, will work in patients with recurrent or unsuccessfully treated Cutaneous T-Cell Lymphoma.EUCTR2012-004766-17-NLKyowa Kirin Pharmaceutical Development, Inc.317
进行中（未招募）
1 期
A clinical trial to test if KW-0761 (an antibody) or a chemotherapy drug, called vorinostat, will work in patients with recurrent or unsuccessfully treated Cutaneous T-Cell Lymphoma.EUCTR2012-004766-17-DEKyowa Kirin Pharmaceutical Development, Inc.317
已完成
3 期
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL)10025321Cutaneous T-cell lymphomaNL-OMON44789Kyowa Kirin Pharmaceutical Development Inc.8